Bavarian Nordic faced a challenging close to 2024, with Q3 revenue falling 26% compared to the same interval in 2023.

Bavarian Nordic AS (BVNKF) reports a robust 62% revenue increase, driven by vaccine success and strategic government ...

Bavarian Nordic A/S (($BVNRY)) has held its Q1 earnings call. Read on for the main highlights of the call. Bavarian Nordic’s recent earnings call ...

The U.S. government is advising that international travelers age 60 and older not get a chikungunya vaccine as it ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Bavarian Nordic’s Vimkunya (recombinant, adsorbed ...

Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three ...

The CDC and FDA advise against Ixchiq chikungunya vaccine for American travellers aged 60 and above. This is due to reported ...

The earnings before interest, tax, depreciation and amortization margin rose to 31% from 3%, and Bavarian Nordic maintained guidance for a full-year EBITDA margin of 26%-30% with revenue still seen at ...

TUESDAY, May 13, 2025 (HealthDay News) — U.S. health officials are telling travelers aged 60 and older to avoid a chikungunya ...

Good day and thank you for standing by. Welcome to the Bavarian Nordic Q1 2025 Results, Conference Call and Webcast. At this time all participants will be in a listen-only mode. After the speaker ...

COPENHAGEN, Denmark, May 2, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization in ...

Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2025. Revenue for the first three ...